Late-onset lymphopenia during radiation is associated with an increased risk of tumor recurrence in newly diagnosed pediatric medulloblastoma.
lymphopenia
pediatric medulloblastoma
radiation
recurrence risk
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
21 Apr 2024
21 Apr 2024
Historique:
revised:
11
03
2024
received:
17
10
2023
accepted:
28
03
2024
medline:
22
4
2024
pubmed:
22
4
2024
entrez:
22
4
2024
Statut:
aheadofprint
Résumé
Recent data found a correlation between lymphopenia occurring early during craniospinal radiation therapy (RT) and risk of disease recurrence in newly diagnosed childhood medulloblastoma. However, the population included patients who received chemotherapy prior to or during RT. Here, we investigate the effect of lymphopenia during RT in patients with newly diagnosed pediatric medulloblastoma who were chemotherapy-naïve. We analyzed 79 patients with newly diagnosed medulloblastoma (ages 2-21 years) treated between 1997 and 2013 with craniospinal RT. Log-rank tests were used to determine survival differences, and Cox proportional hazards regression was used to assess associations between patient characteristics and lymphopenia with disease recurrence risk. Eighty-three percent of patients (62/75) had grade ≥3 lymphopenia by RT Week 3, with 95% developing grade ≥3 lymphopenia at some point during therapy. There was no difference in incidence of lymphopenia between those who received proton beam RT (93%) versus photon (97%). Twenty-four of 79 (30%) patients developed disease recurrence at an average 27.0 months after diagnosis. There was higher risk of disease recurrence in patients with grade ≥3 lymphopenia during RT Week 4 (log-rank p = .016; Cox p = .03) and Week 5 (log-rank p = .024; Cox p = .032); after adjusting for clinical risk group, only grade ≥3 lymphopenia at Week 4 remained prognostic (Cox p = .04). No correlation was found between risk of tumor recurrence and early lymphopenia (RT Weeks 0-3) or absolute lymphocyte count (ALC) below the median at any time during RT. Lymphopenia during RT Weeks 4 and 5 correlates with increased risk of tumor recurrence in pediatric patients with newly diagnosed medulloblastoma.
Sections du résumé
BACKGROUND
BACKGROUND
Recent data found a correlation between lymphopenia occurring early during craniospinal radiation therapy (RT) and risk of disease recurrence in newly diagnosed childhood medulloblastoma. However, the population included patients who received chemotherapy prior to or during RT. Here, we investigate the effect of lymphopenia during RT in patients with newly diagnosed pediatric medulloblastoma who were chemotherapy-naïve.
PROCEDURE
METHODS
We analyzed 79 patients with newly diagnosed medulloblastoma (ages 2-21 years) treated between 1997 and 2013 with craniospinal RT. Log-rank tests were used to determine survival differences, and Cox proportional hazards regression was used to assess associations between patient characteristics and lymphopenia with disease recurrence risk.
RESULTS
RESULTS
Eighty-three percent of patients (62/75) had grade ≥3 lymphopenia by RT Week 3, with 95% developing grade ≥3 lymphopenia at some point during therapy. There was no difference in incidence of lymphopenia between those who received proton beam RT (93%) versus photon (97%). Twenty-four of 79 (30%) patients developed disease recurrence at an average 27.0 months after diagnosis. There was higher risk of disease recurrence in patients with grade ≥3 lymphopenia during RT Week 4 (log-rank p = .016; Cox p = .03) and Week 5 (log-rank p = .024; Cox p = .032); after adjusting for clinical risk group, only grade ≥3 lymphopenia at Week 4 remained prognostic (Cox p = .04). No correlation was found between risk of tumor recurrence and early lymphopenia (RT Weeks 0-3) or absolute lymphocyte count (ALC) below the median at any time during RT.
CONCLUSIONS
CONCLUSIONS
Lymphopenia during RT Weeks 4 and 5 correlates with increased risk of tumor recurrence in pediatric patients with newly diagnosed medulloblastoma.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31022Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Upadhyay R, Venkatesulu BP, Giridhar P, et al. Risk and impact of radiation related lymphopenia in lung cancer: a systematic review and meta‐analysis. Radiother Oncol. 2021;157:225‐233. doi:10.1016/j.radonc.2021.01.034
Venkatesulu B, Giridhar P, Pujari L, et al. Lymphocyte sparing normal tissue effects in the clinic (LymphoTEC): a systematic review of dose constraint considerations to mitigate radiation‐related lymphopenia in the era of immunotherapy. Radiother Oncol. 2022;177:81‐94. doi:10.1016/j.radonc.2022.10.019
Damen PJJ, Kroese TE, van Hillegersberg R, et al. The influence of severe radiation‐induced lymphopenia on overall survival in solid tumors: a systematic review and meta‐analysis. Int J Radiat Oncol Biol Phys. 2021;111(4):936‐948. doi:10.1016/j.ijrobp.2021.07.1695
Venkatesulu BP, Mallick S, Lin SH, Krishnan S. A systematic review of the influence of radiation‐induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol Hematol. 2018;123:42‐51. doi:10.1016/j.critrevonc.2018.01.003
Mallick S, RA V, Giridhar P, et al. A systematic review and meta‐analysis of the impact of radiation‐related lymphopenia on outcomes in high‐grade gliomas. South Asian J Cancer. 2022;11(4):361‐369. doi:10.1055/s‐0042‐1753504
Sampson JH, Gunn MD, Fecci PE, Ashley DM. Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer. 2020;20(1):12‐25. doi:10.1038/s41568‐019‐0224‐7
Audi ZF, Saker Z, Rizk M, et al. Immunosuppression in medulloblastoma: insights into cancer immunity and immunotherapy. Curr Treat Options Oncol. 2021;22(9):83. doi:10.1007/s11864‐021‐00874‐9
Bockmayr M, Mohme M, Klauschen F, et al. Subgroup‐specific immune and stromal microenvironment in medulloblastoma. Oncoimmunology. 2018;7(9):e1462430. doi:10.1080/2162402X.2018.1462430
Patel S, Wang S, Snuderl M, Karajannis MA. Pre‐treatment lymphopenia and indication of tumor‐induced systemic immunosuppression in medulloblastoma. J Neurooncol. 2018;136(3):541‐544. doi:10.1007/s11060‐017‐2678‐3
Grassberger C, Shinnick D, Yeap BY, et al. Circulating lymphocyte counts early during radiation therapy are associated with recurrence in pediatric medulloblastoma. Int J Radiat Oncol Biol Phys. 2021;110(4):1044‐1052. doi:10.1016/j.ijrobp.2021.01.035
Gajjar A, Robinson GW, Smith KS, et al. Outcomes by clinical and molecular features in children with medulloblastoma treated with risk‐adapted therapy: results of an international phase III trial (SJMB03). J Clin Oncol. 2021;39(7):822‐835. doi:10.1200/JCO.20.01372
Gajjar A, Chintagumpala M, Ashley D, et al. Risk‐adapted craniospinal radiotherapy followed by high‐dose chemotherapy and stem‐cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma‐96): long‐term results from a prospective, multicentre trial. Lancet Oncol. 2006;7(10):813‐820. doi:10.1016/S1470‐2045(06)70867‐1
Ebrahimi S, Lim G, Liu A, et al. Radiation‐induced lymphopenia risks of photon versus proton therapy for esophageal cancer patients. Int J Part Ther. 2021;8(2):17‐27. doi:10.14338/IJPT‐20‐00086
Gaikwad U, Bajpai J, Jalali R. Combinatorial approach of immuno‐proton therapy in cancer: rationale and potential impact. Asia Pac J Clin Oncol. 2023;20:188‐197. doi:10.1111/ajco.13966
De B, Ng SP, Liu AY, et al. Radiation‐associated lymphopenia and outcomes of patients with unresectable hepatocellular carcinoma treated with radiotherapy. J Hepatocell Carcinoma. 2021;8:57‐69. doi:10.2147/JHC.S282062
Cunningham D, Zaniletti I, Breen W, et al. Lymphopenia in pediatric patients following proton radiotherapy. Int J Radiat Oncol Biol Phys. 2021;111(3):e173.
Chou B, Hopper A, Elster J, et al. Volumetric de‐escalation and improved acute toxicity with proton craniospinal irradiation using a vertebral body‐sparing technique. Pediatr Blood Cancer. 2022;69(5):e29489. doi:10.1002/pbc.29489
Ellis RE. The distribution of active bone marrow in the adult. Phys Med Biol. 1961;5:255‐258. doi:10.1088/0031‐9155/5/3/302
Liu KX, Ioakeim‐Ioannidou M, Susko MS, et al. A multi‐institutional comparative analysis of proton and photon therapy‐induced hematologic toxicity in patients with medulloblastoma. Int J Radiat Oncol Biol Phys. 2021;109(3):726‐735. doi:10.1016/j.ijrobp.2020.09.049
Wang F, Cathcart SJ, DiMaio DJ, et al. Comparison of tumor immune environment between newly diagnosed and recurrent glioblastoma including matched patients. J Neurooncol. 2022;159(1):163‐175. doi:10.1007/s11060‐022‐04053‐0
Turner CP, McLay J, Hermans IF, et al. Tumour infiltrating lymphocyte density differs by meningioma type and is associated with prognosis in atypical meningioma. Pathology (Phila). 2022;54(4):417‐424. doi:10.1016/j.pathol.2021.10.002
Pages F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128‐2139. doi:10.1016/S0140‐6736(18)30789‐X
Bienkowski M, Preusser M. Prognostic role of tumour‐infiltrating inflammatory cells in brain tumours: literature review. Curr Opin Neurol. 2015;28(6):647‐658. doi:10.1097/WCO.0000000000000251
Shadbad MA, Asadzadeh Z, Hosseinkhani N, et al. A systematic review of the tumor‐infiltrating CD8+ T‐cells/PD‐L1 axis in high‐grade glial tumors: toward personalized immuno‐oncology. Front Immunol. 2021;12:734956. doi:10.3389/fimmu.2021.734956
Kmiecik J, Poli A, Brons NH, et al. Elevated CD3+ and CD8+ tumor‐infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol. 2013;264(1‐2):71‐83. doi:10.1016/j.jneuroim.2013.08.013
Mauldin IS, Jo J, Wages NA, et al. Proliferating CD8+ T cell infiltrates are associated with improved survival in glioblastoma. Cells. 2021;10(12):3378. doi:10.3390/cells10123378
Safaei S, Mohme M, Niesen J, Schuller U, Bockmayr M. DIMEimmune: robust estimation of infiltrating lymphocytes in CNS tumors from DNA methylation profiles. Oncoimmunology. 2021;10(1):1932365. doi:10.1080/2162402X.2021.1932365
Sharma R, Katiyar V, Gurjar H, Sharma M, Goda R, Vora Z. Is medulloblastoma associated with systemic immunomodulation?—a comparative analysis of preoperative inflammatory markers. Surg Neurol Int. 2020;11:86. doi:10.25259/SNI_336_2019
Vermeulen JF, Van Hecke W, Adriaansen EJM, et al. Prognostic relevance of tumor‐infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma. Oncoimmunology. 2018;7(3):e1398877. doi:10.1080/2162402X.2017.1398877
Murata D, Mineharu Y, Arakawa Y, et al. High programmed cell death 1 ligand‐1 expression: association with CD8+ T‐cell infiltration and poor prognosis in human medulloblastoma. J Neurosurg. 2018;128(3):710‐716. doi:10.3171/2016.11.JNS16991